Journal of pediatric hematology/oncology · 2026
Long-term Survival and Relapse Patterns in Pediatric Hepatoblastoma: A 20-year Single-center Experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ertekin Mehtap, Temuroglu Aytul, Celik Fatih, Demirkaya Metin, Sevinir Betul
Аннотация
BACKGROUND: Despite advancements, managing high-risk and metastatic hepatoblastoma remains challenging. This study evaluates 2 decades of clinical experience to identify long-term prognostic drivers and the evolving role of event-free survival (EFS).
METHODS: This cohort consisted of 39 children with hepatoblastoma from 2004 to 2024. The clinical characteristics, PRETEXT, risk group, alpha-fetoprotein level, pulmonary metastasis, and treatment modalities were reviewed. The overall and event-free survival were estimated using the Kaplan-Meier method and log-rank tests. Univariable Cox regression was performed to evaluate the impact of pulmonary metastasis on EFS.
RESULTS: The mean age at diagnosis was 3.6±4.3 years. The 5-year OS and EFS rates were 81.2% and 75.0%, respectively. Six deaths and 9 events were recorded. OS was not significantly influenced by risk group (P=0.093), PRETEXT stage (P=0.177), and AFP (P=0.214). Pulmonary metastasis at diagnosis was associated with poor EFS (log-rank P=0.048). In the univariable Cox model for EFS, pulmonary metastasis was associated with a higher risk for events (HR 3.83, 95% CI 0.91-16.10, P=0.067).
CONCLUSIONS: Long-term overall survival was favorable in this cohort. Pulmonary metastasis emerged as the variable most closely linked to inferior event-free survival, whereas traditional clinical and staging variables were not significantly associated with overall survival.
METHODS: This cohort consisted of 39 children with hepatoblastoma from 2004 to 2024. The clinical characteristics, PRETEXT, risk group, alpha-fetoprotein level, pulmonary metastasis, and treatment modalities were reviewed. The overall and event-free survival were estimated using the Kaplan-Meier method and log-rank tests. Univariable Cox regression was performed to evaluate the impact of pulmonary metastasis on EFS.
RESULTS: The mean age at diagnosis was 3.6±4.3 years. The 5-year OS and EFS rates were 81.2% and 75.0%, respectively. Six deaths and 9 events were recorded. OS was not significantly influenced by risk group (P=0.093), PRETEXT stage (P=0.177), and AFP (P=0.214). Pulmonary metastasis at diagnosis was associated with poor EFS (log-rank P=0.048). In the univariable Cox model for EFS, pulmonary metastasis was associated with a higher risk for events (HR 3.83, 95% CI 0.91-16.10, P=0.067).
CONCLUSIONS: Long-term overall survival was favorable in this cohort. Pulmonary metastasis emerged as the variable most closely linked to inferior event-free survival, whereas traditional clinical and staging variables were not significantly associated with overall survival.